Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VBVT(.508)...change in business direction.....
Authorized share increase......
YBGJ(.575)...increased my position.....
I still hold all of the shares I have purchased. I accumulated an additional 9,250 shares today in the .55-.80 range. Currently hold 22,750 shares at an average under .54 per share.
In hindsight I should have sold at least half of my position when YBGJ made its move into the $3-4 range. When the reverse merger occurred, I was initially expecting to see a fair amount of churning when the stock first made its move over the $1 level. I really like the potential of this reverse merger so I was planning to hold through all of that churning and then maybe try to sell some shares if/when the stock had a nice breakout after that consolidation. But that expected churning never really occurred and the stock seemed to move to the $3 level relatively easily/quickly.
At that point I decided to just hold my shares, figuring the consolidation I had initially anticipated might instead occur at a higher price ($2-3 range). But the bottom kind of fell out and the overall market downturn did not help anything.
So here we are again, back at the sub-dollar level. Let me preface my positive comment in the paragraph below by stating there is always the possibility this pullback in the stock might be the harbinger of an upcoming bad financing deal. I am anticipating that YBGJ will probably be arranging a sizable financing package at some point. That has the potential to be either negative or positive for the stock.
At this moment in time, and at this stock price/valuation, I am definitely bullish on YBGJ and optimistic about the prospects/chances of seeing prices above $3 again. I have increased my position in anticipation of possible catalysts coming (filings, financings, increased corporate activity, etc.). The company changed the end of its fiscal year to December, so between now and the end of May (give or take a couple of weeks) we should be getting the 2020 10-K and 2021 Q1 filings.
Corporate activity should start to ramp up this year. According to the YBGJ leadership/management conference that was held at the end of February, additional people were officially appointed to positions in the company. New products are expected to be launched soon.......
https://mp.weixin.qq.com/s/LRwy06DJNoaq2zFR2Chutw
I am aware that at least one of the Viv Cell franchise stores is officially open and operating in a shopping mall. I am pretty sure this store opened just very recently (maybe within the last month). All of the reviews and most of the photos of the store in the links below did not exist when I first ran across this last week......
http://www.dianping.com/shop/H1fLOvGXKGQbXmkV
http://www.dianping.com/shop/H1fLOvGXKGQbXmkV/photos
According to the most recent media report I have noticed (dated March 17), construction of Yubo's $17M new headquarters and R&D center was expected to begin around February/March......
PHBR...increased my position......
ANAS(.10)...legacy share valuation, Lazar's control shares.....
QMDT(.029)...$256K SBIR Phase I grant......
Back around mid-February, dark QMDT moved over the ten-cent level when news started spreading about a $100K grant the company had received for work on antimicrobial coatings to be applied on hard surfaces. I trimmed off enough shares on the February move to basically make my remaining position free.
Now on March 19, QMDT was awarded a $256K grant for work on regenerable antimicrobial paints. The project starts April 1 and is expected to be completed at the end of September.
The CEO also did another interview with The Wall Street Transcript (posted on the site on March 18). He usually does these interviews about once or twice a year. I did not purchase this one, so I don't know if it contained any interesting/helpful bits of information.
I've bought a few more shares in case QMDT experiences another strong move. Below is the abstract for this particular project/grant. I've placed in bold some wording that caught my eye......
splintered sunlight...regarding ZNNC......
EAIN...increased position......
AMSA(.055)...accumulated a position......
58.5M outstanding
3.5M unrestricted
Picked up a position in AMSA this month in the .04-.055 range. I wanted to get some shares ahead of a possible reverse merger here. It doesn't look like a lot of investors have this shell on their radars.
From the Q3 filed in November 2020......
ZNNC...current website, recent changes.....
EAIN($3.75)...increased my position yesterday......
Added another 1.5K shares to my position yesterday, mostly in the $3.35-3.50 range. The reason for increasing my shares is pretty much explained in the post below. Definitely high-risk, but given how few investors are aware of the change-in-control, the potential for some upcoming catalysts, and the extremely low amount of shares available for trading, I figure it is worth taking a chance at these price levels......
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162277310
Also, while doing some internet searches in the last few days I noticed this March 4, 2021 article in China regarding the company that has purchased control of the EAIN shell. This is a translated version of the article. I've placed in bold the description of Plural Industry Holding Group.......
splintered sunlight...regarding PHBR.....
EAIN($2.90)...change in control February 5.......
Picked up a few more shares of the EAIN shell today. Still holding all of the shares I accumulated previously (currently averaged in under $1.22 per share). The Q3 report filed over the weekend disclosed that David Lazar sold controlling interest in this shell......
Lucosky Brookman, LLP...new corporate securities counsel.....
Should be getting closer now to some additional updates to OTC Markets and perhaps filings. Based on the recent update to the GSAC corporate website, it looks like GSAC has hired Lucosky Brookman, LLP as the securities counsel. It appears Lawrence Metelitsa will be handling the GelStat account......
https://www.lucbro.com/lawrence-metelitsa
https://gelstat.com/investors/company-information/ir-contacts
QGSI(.25)...a few observations......
Uboat...regarding ZNNC......
ZNNC(.011)...additional changes to website.....
RIGG...accumulated a position......
Over the last couple/few months I accumulated about 1.9K shares of the RIGG shell at an average around $1.02 per share. Probably could have bought an additional 1K shares in the $1-2 range if I had been more aggressive/alert in my buying.
I don't know what the current status of this shell is. It looks like the shell was relatively clean at the time David Lazar was making OTC Markets filings. The only thing a bit interesting/unusual I noticed while reading through the filings was that Lazar was suppose to inject $120+K into the shell in exchange for a control block of 137,400 shares. It appears that did not occur, which is why the outstanding share count is still at 113K.
All things considered, if that verified share count on the OTC Markets profile page is indeed accurate, I figured that RIGG was a good speculative "no-brainer" around that $1 dollar area. That unrestricted share count of 38K could lead to some pretty interesting price movements in this shell.
PHBR(.1099)....increased my position.....
February 2021 corporate presentation.....
That new corporate presentation QGSI put up on its website is pretty interesting......
https://docsend.com/view/3trzhvt
A few items of interest from that presentation.....
1) QGSI's technology can be integrated directly into charting platforms.
2) There are an additional 37+ financial exchanges and 300+ crypto exchanges in the pipeline.
3) The commercialization timeline on page 17 mentions B3 Exchange certification in early 2021. That is the Brazil stock exchange. The company expects to double the number of certified brokers (from 10 to 20) by the end of this year.
4) Page 16 has the growth/revenue projections. It looks like they are expecting measurable revenues to begin around Q3 2021 and then begin a significant acceleration ramp starting around Q1 2022. If QGSI can come anywhere close to the kind of growth/revenue they are expecting in this presentation, this stock should perform well and will likely make a move to the NASDAQ at some point.
Quantum Works...Juan Arturo Silva-Ordaz......
Here's our office pic.twitter.com/2RRRRMyihQ
— Quantum Works (@QuantumWorksMX) June 22, 2017
Alt 5 Sigma...social media post......
Yesterday afternoon Alt 5 Sigma made what I think is a somewhat interesting post on its social media accounts......
If you are currently trading cryptocurrencies, then we have something very exciting for you!
— ALT 5 Sigma (@alt_sigma) January 22, 2021
Sign up to our watch list and get notified when we launch an application that will change they way you trade!https://t.co/b2gFj3gMSZ#Bitcoin #Ethereum #Litecoin #ChainLink #crypto pic.twitter.com/Be9q4HF4qp
January 14 8-K...a couple of observations.....
The OTC Markets profile page needs to get fully updated, and a more investor friendly/updated corporate website needs to be deployed. But assuming the company executes on its plans, and becomes active in the investor relations side of being a public company, there should be a number of opportunities for very nice IR-activity through much of this year.
The stock has managed to get to the $3 price area with minimal buying interest and minimal IR assistance. Should be somewhat interesting to see what might happen if the news flow begins/intensifies as the operational activity increases.
A couple of observations from the January 14 8-K......
1) Based on the information in that filing, it looks like the earliest the company began generating its first revenues was in April 2020. Gross margin was over 91%, which is quite interesting because included in that revenue was 300 of its nebulizers (medical devices to deliver the inhalant). I have no idea if that margin percentage is just an aberration or if it is indicative of what YBGJ might generate going forward on its product-related revenue. Margin percentages anywhere close to that would be excellent.
2) Kind of interesting to note that on September 11, 2020, shortly before Lina Liu purchased control of the MAGAA shell, an individual investor (Cheung Ho Shun) made a pretty large investment in Platinum International Biotech (he purchased 1.5% of the company). Post reverse merger, his $750K investment equals 1,755,000 shares of YBGJ with a cost basis a little under 43 cents per share.
Headquarters ceremony video news coverage.....
8totrade website registration......
Cardoso November 8 interview...quantum computing......
Two months ago CEO Leonardo Cardoso did a 1.47 hour long Instagram interview with Gleison Gambogi (a trader in Brazil). It has more than 2.1K views. Although the interview is in Portugese, it is pretty obvious that most of the interview is spent talking about QuantGate's technology. Cardoso appears in the video starting around the 3:45 minute mark.
In the comments section to the right of the interview, scroll down to a comment made by "sirdods". Cardoso's response to this comment is pretty interesting......
Correction to a typing mistake in previous post...
Collins/Swain share movement, amended note conversion terms......
The OTCQB certification filing yesterday provided some interesting and potentially positive bits of information......
1) The two sisters (Marsha Collins and Debra Swain) either gifted or sold 25 million shares from the Four Seasons Trust. It looks like CTO Ilan Yosef received 5 million of those shares. It has long been my contention that movement of the shares that the sisters own is something that might start raising some eyebrows and trigger more interest in the company/stock. Whether that movement of shares ultimately becomes a positive or negative thing remains to be seen, but at this moment I am viewing it as something very positive.
2) Throughout 2020 a number of people loaned/invested some pretty sizable chunks of money to QGSI. Nikolas Perrault (an advisor to QuantGate) arguably knows more about the history of QGSI than just about anyone else currently associated with the company. He increased his financial exposure to the company by almost $200K in October.
3) It is not clear from the filing what the current terms of the notes are, but it appears (and I stress the word "appears") to me that the company is eliminating the floorless convertible feature that existed before and is now setting a conversion floor at 25 cents. A nice premium to the current share price of 14 cents. If the previous note terms have indeed been scrapped and the note holders are now being given the option below, I think this is a very positive development. It should help reduce the potential for negative manipulation of the share price........
February 6...headquarters ceremony, marketing strategy conference......
YBGJ held a ceremony yesterday for the transfer of its headquarters from Beijing to Chengdu. They also held a marketing strategy conference on the same day. A few snippets of interesting items from that ceremony and conference......
1) The groundbreaking ceremony marked the official transfer of the headquarters of Feibo International Group from Beijing to Chengdu, and also the official start of Feibo International's industrialization journey. Feibo International Group is a high-tech enterprise group focusing on the development and application of stem cell technology. Relying on the endometrial stem cell storage business, the group is committed to building the world's first endometrial stem cell public bank with scale advantages.
2) Chengdu Yubo (Yubo Global Biotechnology (Chengdu) Co., Ltd.) is a wholly-owned holding company of Yubo Biotechnology (Hong Kong) in China. It is the main company of Yubo Group's overseas listed companies in China and has strong assets. The total investment amounts to 50 million US dollars. Located in the global biomedical technology transformation center-Chengdu Medical City Third Medical Innovation Center, it has laboratories and cell storage warehouses, cell intelligent preparation platforms and medical device production lines that meet the latest standards.
3) With the support of the government and the park (Chengdu Medical City), Feibo International will also cooperate with universities and tertiary hospitals in the park to establish legal and compliant scientific research projects and carry out various special subjects for the clinical application of stem cells.
4) The chairman also specifically talked about the strategy of Viv-CELL Biotechnology Experience Center physical stores of Feibo International in 2021 and the specific requirements for opening stores and franchising. Ms. Liu Lina, Chief Financial Officer of Feibo International, explained to senior executives the upgrade of financial standards facing the rapid development of the group.
https://tinyurl.com/y2vfatev
PHBR(.079)...finished accumulating a position......
I completed accumulation of a core position in the PHBR shell today with some purchases under the 8-cent level. I'm currently averaged in at .0551 per share, which represents a legacy share valuation on this shell of just a little over $600K (see post below for legacy share valuation explanation).
Although there is never any guarantee of a successful/profitable outcome, the risk/reward at this kind of valuation on a fully-reporting Lazar shell is extremely attractive. Especially considering the types of multi-million dollar legacy valuations we are seeing on shells in the recent weeks/months. Paying attention to the legacy valuation on your cost-basis position can help mitigate (to some extent) the potential negatives of any share structure change (split, dilution, etc.). And leaves you nicely positioned to participate if momentum buying develops.
It should be interesting to see what Ross Dimaggio has planned for this shell. He has spent many years in the business world and the area of investor relations, so he has probably developed a lot of connections to potential RM candidates. If he didn't purchase PHBR as a placeholder for a third-party type of RM, it would probably be reasonable to assume/guess that he might bring his private equity and venture capital company (Switchback Capital) public via this shell.
YBGJ($3.25)...adjusting my personal targets higher.....
8totrade app...QuantGate podcast......
1) 8totrade app: Anthony Munns briefly mentioned the 8topuz/QuantGate mobile trading application on a December 21 episode of The Fintech Files podcast. He said "it's a little bit hush-hush right now", but they are hoping to release it in Q1 of 2021. His statement/comments about the app can be heard around the 18:15 to 19:05 minute marks......
PHBR(.0625)...increased my position......
ZNNC(.0024)...some updates to the website....
EAIN($1.51)...splintered sunlight.....
8totrade...Pilot Trading Overview video.....
1)
Additional info/pictures...listing ceremony.....
Last night and this morning Yubo has been updating/changing the corporate news section on its website. A more lengthy account of the December 8 conference/forum is now on its corporate website. It includes an additional 14 pictures from the event.
The morning forum session was primarily focused on general items related to the stem cell industry (applications, market prospects, etc). The afternoon session was heavily focused on items specific to Yubo/YBGJ -- its path to an American listing, current/future plans, etc.
Below is some translated text and a picture from the YBGJ-listing ceremony part of the afternoon session.....
http://www.yubogroup.com/details/info2-2.html
December 8 Beijing ceremony.....
YBGJ...encouraged by what I am seeing......
8topuz/QuantGate...possible launch in December.....